title: Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer.
abstract: Sixty patients, 29 with limited disease and 31 with extensive disease, received an infusion cisplatin-based chemotherapy regimen and, where applicable, subsequent hyperfractionated thoracic radiation therapy (HTRT). Of the patients with limited disease, the response rate was 100% (76% complete response); median survival 26.5 months; 1- and 2-year survival 90 and 55%, respectively. Of those with extensive disease,96% responded (36% complete response) with median survival 12.0 months and 1- and 2-year survival 48 and 29%, respectively. Thirty-five percent of extensive disease patients were downstaged to a "limited" status. with a median survival of 20.3 months. Grade IV leukopenia and thrombocytopenia were seen in 25 and 7% of patients, respectively, with one patient dying of radiation pneumonitis. Within the constraints of the study, infusion cisplatin-based chemotherapy and HTRT appear to be a safe and effective program for the treatment of small-cell lung cancer.
authors.affiliation: Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: S
authors.initials: S
authors.lastname: Frytak
authors.forename: E G
authors.initials: EG
authors.lastname: Shaw
authors.forename: J R
authors.initials: JR
authors.lastname: Jett
authors.forename: R L
authors.initials: RL
authors.lastname: Richardson
authors.forename: R L
authors.initials: RL
authors.lastname: Foote
authors.forename: E T
authors.initials: ET
authors.lastname: Creagan
authors.forename: R T
authors.initials: RT
authors.lastname: Eagan
authors.forename: J Q
authors.initials: JQ
authors.lastname: Su
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002423:Cause of Death; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000209:etiology; D008168:Lung / Q000528:radiation effects*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D017564:Radiation Pneumonitis / Q000209:etiology; D012074:Remission Induction; D015996:Survival Rate; D013921:Thrombocytopenia / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin